Targeting anaplastic lymphoma kinase (ALK) alleviates synaptic dysfunction associated with C9orf72 haploinsufficiency
Our findings highlight the therapeutic potential of lorlatinib, an ALK inhibitor, in mitigating synaptic deficits caused by C9orf72 haploinsufficiency. We emphasize the role of synaptic pathology in C9orf72-FTD pathogenesis and suggest that targeting ALK with drugs like lorlatinib could offer promising therapeutic strategies for treating synaptic dysfunction caused by C9orf72 haploinsufficiency.
Authors
- Liliana Attisano (ORCID: https://orcid.org/0000-0003-4824-2642)
- Bryan Kartono (ORCID: https://orcid.org/0000-0001-5177-1663)
- Janice Robertson
Institutions
- University of Toronto (CA)
- Occupational Cancer Research Centre (CA)
Publication Details
- Journal
- Alzheimer s & Dementia
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1002/alz70855_099957
- Primary Topic
- Amyotrophic Lateral Sclerosis Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00